DSM-Firmenich AG (DSFIY)
| Market Cap | 27.52B +24.7% |
| Revenue (ttm) | 10.35B +10.1% |
| Net Income | -1.61B |
| EPS | -6.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 25.39 |
| Dividend | 0.24 (2.15%) |
| Ex-Dividend Date | May 12, 2026 |
| Volume | n/a |
| Open | 11.07 |
| Previous Close | 11.11 |
| Day's Range | 11.07 - 11.22 |
| 52-Week Range | 6.40 - 11.24 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 18, 2027 |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes,... [Read more]
News
India investigates fragrance giants over price collusion, document shows
Global fragrance makers Givaudan , Firmenich and International Flavors & Fragrances face a second antitrust investigation by Indian authorities, according to a regulatory document seen by Reuters.
Dsm-firmenich's fragrance-led core profit beat sends shares higher
Dsm-firmenich on Thursday beat market expectations for second-quarter core earnings and said full-year sales growth should reach the upper end of its target range on the back of broad-based volume gr...
DSM-Firmenich AG Earnings Call Transcript: Q2 2026
Strong H1 and Q2 results with robust sales and EBITDA growth, margin improvement, and solid cash generation. Outlook for 2026 is reaffirmed, with cost programs and innovation pipeline supporting future growth, while FX headwinds and restocking effects are closely monitored.
DSM-Firmenich AG Slides: Q2 2026
DSM-Firmenich AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
DSM-Firmenich AG Earnings release: Q2 2026
DSM-Firmenich AG released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
dsm-firmenich receives FDA approval on PARSOL® Shield, a new sun protection ingredient for the U.S.
Press Release dsm-firmenich receives FDA approval on PARSOL® Shield, a new sun protection ingredient for the U.S. Kaiseraugst (Switzerland), Maastricht (Netherlands), June 10, 2026 dsm-firmenich, inno...
dsm-firmenich shares commence trading on SIX Swiss Exchange, establishing dual listing with Euronext Amsterdam
Press Release dsm-firmenich shares commence trading on SIX Swiss Exchange, establishing dual listing with Euronext Amsterdam Kaiseraugst (Switzerland), Maastricht (Netherlands), May 21, 2026 dsm-firme...
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2026
Press Release dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2026 Kaiseraugst (Switzerland), Maastricht (Netherlands), May 7, 2026 dsm-firmenich, innovators in nutrition,...
DSM-Firmenich AG Earnings Call Transcript: Q1 2026
Solid Q1 with 4% volume-driven sales growth and strong Perfumery and Beauty performance. Full-year outlook reaffirmed, margins expected to improve as FX and cost impacts are managed. Dual listing on SIX Swiss Exchange announced to broaden investor base.
DSM-Firmenich AG Earnings release: Q1 2026
DSM-Firmenich AG released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
dsm-firmenich Q1 2026 trading update
Press Release Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2026 dsm-firmenich Q1 2026 trading update Solid start to the year driven by good LFL sales growth Highlights 4% LFL sales grow...
DSM-Firmenich AG Transcript: Investor update
The company has completed its transformation, focusing on specialty ingredients and creation capabilities, with strong progress in synergies, sustainability, and financial performance. 2026–2028 targets include 2%-4% organic sales growth (rising to 4%-6% plus Bovaer), EBITDA margin of 20%-23%, and cash conversion above 14%.
DSM-Firmenich AG Press release: Investor update
DSM-Firmenich AG issued a press release on March 12, 2026, disclosing material business information to investors.
DSM-Firmenich AG Slides: Investor update
DSM-Firmenich AG has posted slides in relation to its latest quarterly earnings report, which was published on March 12, 2026.
dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation
Press Release dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation Kaiseraugst (Switzerland), Maastricht (Netherlands), March 12, 2026...
dsm-firmenich announces share repurchase program to cover share plans and reduce capital
Press Release dsm-firmenich announces share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 12, 2026 dsm-firmenich, innovators in ...
dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program
Press Release dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program Kaiseraugst (Switzerland), Maastricht (Netherlands), February 26 2026 dsm-firmenich, i...
dsm-firmenich publishes 2025 Integrated Annual Report
Press Release dsm-firmenich publishes 2025 Integrated Annual Report Kaiseraugst (Switzerland), Maastricht (Netherlands), February 20, 2026 dsm-firmenich today announces the publication of its Integrat...
dsm-firmenich issues €1.5 billion long-term bonds
Press Release dsm-firmenich issues €1.5 billion long-term bonds Kaiseraugst (Switzerland), Maastricht (Netherlands), February 17 2026 dsm-firmenich today announces the successful launch of a €1.5 bill...
DSM-Firmenich AG Earnings Call Transcript: Q4 2025
Divestment of ANH refocuses the business on nutrition, health, and beauty, with 3% organic sales growth in 2025 and a resilient EBITDA margin near 20%. Cash conversion remains strong, and midterm targets for growth and margin are unchanged, with an upward revision to the cash target expected.
DSM-Firmenich AG Annual report: Q4 2025
DSM-Firmenich AG has published its Q4 2025 annual report on February 12, 2026.
DSM-Firmenich AG Earnings release: Q4 2025
DSM-Firmenich AG released its Q4 2025 earnings on February 12, 2026, summarizing the period's financial results.
DSM-Firmenich AG Slides: Q4 2025
DSM-Firmenich AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH)
Press Release dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Kaiseraugst (Switzerland), Maastricht (Netherlands), February...
DSM-Firmenich AG Transcript: Status update
Divestment of Animal Nutrition & Health to CVC for EUR 2.2 billion enables a focused consumer business, with a 20% retained stake and favorable vitamin supply terms. Share buyback and stable dividend reflect confidence in future cash flow, while restated financials and strategic targets will guide the next phase.